Jinwon Life Sciences Subsidiary VGXI Forms Strategic Partnership with Sutro Biopharma

Jinwon Life Sciences announced on the 4th that its subsidiary VGXI, a leading contract development and manufacturing organization (CDMO) in the field of nucleic acid biopharmaceuticals such as gene therapy, DNA vaccines, and RNA drugs, has formed a strategic partnership with Nasdaq-listed Sutro Biopharma, Inc. VGXI will be responsible for producing plasmid DNA used in clinical trials of luveltamab tazevibulin (luvelta), an antibody-drug conjugate (ADC) anticancer agent developed by Sutro Biopharma.

Sutro Biopharma, a clinical-stage ADC anticancer drug developer targeting ovarian cancer, recently initiated Part 2 studies for the global Phase 2/3 clinical trial of luvelta. VGXI will produce and supply the plasmid DNA required for Sutro Biopharma’s XpressCF cell-free expression system for luvelta manufacturing using a 1500L fermenter.

Youngkeun Park, CEO of Jinwon Life Sciences, said, “We are pleased to establish a strategic partnership to support not only the clinical production of luvelta but also all ongoing projects of Sutro Biopharma. Our company’s expertise and technology in large-scale plasmid DNA production will play a crucial role in advancing and commercializing Sutro Biopharma’s promising therapeutics in late-stage clinical development.”

Dr. Venkatesh Srinivasan, Chief Technology and Operations Officer of Sutro Biopharma, stated, “The partnership with VGXI has laid the foundation for further activating the cell-free manufacturing platform at a commercial scale as leading drug candidates progress into clinical development.”

This content was produced with the assistance of AI translation services.